Nilotinib early switch efficacy in non-optimal responder CML patient after first line imatinib treatment
We report a case of a patient with chronic myeloid leukemia in chronic phase who was treated with Imatinib as first line therapy. He showed a suboptimal response by 2006 ELN criteria after six months, for this reason we performed a mutational analysis that showed the mutation F486S. Due to this find...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SEEd
2015-10-01
|
| Series: | Clinical Management Issues |
| Subjects: | |
| Online Access: | https://journals.seedmedicalpublishers.com/index.php/cmi/article/view/1133 |